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The aim of this study was to determine the prevalence of potential drug-drug interactions (pDDIs), to identify drugs 
frequently involved in interaction and to identify factors associated with pDDIs in medical wards of Tikur Anbessa 
Specialized Hospital (TASH). A prospective crossectional study was conducted on 163 patients admitted in medical 
wards of TASH. Presence of interaction was cheeked using medscape drug-drug interaction checker. Data was 
analysed using SPSS version 21. A test of association was done using binary and multiple logistic regressions. The 
overall prevalence of potential drug-drug interaction was 86.5%. Interactions of major severity account for about 
one fifth of total pDDIs. The number of drugs taken by the patient was found to be significantly associated with 
pDDIs. The study highlighted the need to carefully select drugs and implement active pharmaceutical care services 
in order to prevent harmful effect of these interactions. 
 




As the number of patients with multiple co 
morbidities is increasing the drug therapy also 
becomes more complex. The use of complex drug 
regimen in turn will significantly increase the risk of 
DDI. [1] DDI is a situation in which one drug affects 
the activity of another when both are administered 
together. [2] DDIs can be either pharmacokinetic or 
pharmacodynamic type. Pharmacokinetic interactions 
are caused by differences in the absorption, transport, 
distribution, metabolization or excretion of one or 
both of the drugs compared with the expected 
behaviour of each drug when taken individually. 
Pharmacodynamic drug-drug interactions occur 
when drugs act at the same or interrelated receptor 
sites, resulting in additive, synergistic, or antagonistic 
effects of each drug at the target receptor. [3] DDIs 
may result in increased or decreased efficacy, 
treatment failure as well as increased toxicity of 
medications.[4,5] Hospitalized patients are more likely 
to be affected by these DDIs because of severe and 
multiple illnesses, co-morbid conditions, chronic 
therapeutic regimens, poly-pharmacy and frequent 
modification in therapy.[6] 
  
Assessment and categorization of drug-drug 
interactions on the basis of severity is very important 
in order to decide on the risk versus benefit 
alternatives. On the basis of severity, drug-drug 
interactions are categorized as minor, moderate and 
severe. Minor drug interactions do not result in any 
significant troublesome outcomes. Management of 
these types of interactions is usually not required. 
Moderate drug-drug interactions could result in 
worsening of clinical condition of the patient. 
Treatment to manage such type of interactions could 
be considered. Major drug-drug interactions could 
lead to life threatening condition; therefore it should 
be considered essential to address such problems as 
soon as they are identified. 
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DDIs may cause adverse drug reactions (ADR) which 
may lead to hospitalization and emergency 
department visit. The estimated proportion of patients 
receiving interacting drugs with potential for an ADR 
or changes in therapeutic effect varies between 
0.63% and 56% depending on the study. [7-10] The 
differences are due to study design, study population 
and study time periods. One study reported that 
Among the 156 ADRs with at least one theoretical 
DDI, 41% could be explained by a DDI. [11] ADR 
because of DDI also contributes for about 2.8% of 
hospital admissions per year. [12] Another study 
showed 1% of all hospital admissions were caused by 
drug–drug interactions (DDIs), corresponding to 16% 
of all patients admitted with ADRs. [11] In a geriatric 
outpatient cohort 21.3% of patients are experiencing 
at least one ADR as a consequence of a DDI.[9] 
Prospective study conducted in an internal medicine 
department in Cluj-Napoca, Romania showed that 
25.9% of all validated ADRs were consequences of 
drug interactions.[13] A study conducted in 
Switzerland reported that 56.2 % of patients were 
exposed to one or more major or moderate pDDIs in 
internal medicine ward.[14] 1.5% of hospitalised 
patients had a diagnosis related to an ADR. Of these, 
a DDI was identified in 68% and a severe interaction 
in 12% respectively.[15] The incidence of DDI related 
adverse drug reactions is 6% in elderly outpatients. 
[16] 
 
Reports of similar studies are common world-wide. 
However to the best of my knowledge there are few 
studies about drug-drug interaction and associated 
factors among hospitalized patients in Ethiopia. The 
increasing complexity of medication regimens of the 
patients, as well as the fragmented health care system 
in Ethiopia, with multiple prescribers for one patient 
are important elements that might lead to DDIs.  
Since DDIs are important causes for increase in 
morbidity and mortality rates in hospitalised 
patients,[17] it is imperative to assess the insight of 
pDDIs in hospitalised patients. Hence, the present 
study was undertaken to determine the prevalence of 
potential drug-drug interactions, to identify drugs 
frequently involved in interaction and to identify 
factors associated with pDDIs among hospitalized 
patients in medical wards of Tikur Anbessa 




Study area and design: This prospective cross-
sectional study was conducted in the medical wards 
of Tikur Anbessa Specialized Hospital, Addis Ababa, 
Ethiopia for a period of 3 months (June - August, 
2014). The hospital has more than 600 beds and gives 
diagnostic and treatment service for about 370,000-
400,000 patients per year.[18] one hundred sixty three 
patients were included in the study by using simple 
random sampling method.  
 
Study subjects: Patients admitted consecutively to 
Internal medicine wards were included in the study. 
Demographic information (age and sex), length of 
hospital stay, main diagnosis, number of drugs and 
details of co-morbidities were obtained from the 
clinical records. Subjects who were included in the 
study were those with age greater than 14 years, 
hospital stay of 24 hr and above and patients 
prescribed with at least two medications. 
 
Data collection and analysis: The data collection 
process was supervised; all filled data abstraction 
formats were reviewed and cheeked for their 
completeness every day. All medications that were 
prescribed were screened for potential DDIs. Taking 
more than 5 drugs /day was considered as poly 
pharmacy.[19,20]  Potential DDIs were detected using 
medscape Drug Interactions Checker. All drugs in a 
patient’s medication profile were entered one by one 
into the software. The software displays all 
interacting combination(s) present in the medication 
profile. It also provides information about the 
mechanism and potential adverse outcomes of an 
interaction. All identified-pDDIs were categorized on 
the basis of their levels of severity and mechanism of 
interaction.  
 
On the basis of severity medscape drug interaction 
checker categorizes DDIs as minor, moderate and 
major. Those interactions that may potentially result 
in life-threatening outcomes and need medical 
interventions are considered as major DDIs. 
Moderate DDIs cause potential deterioration of 
clinical condition and may require a change in 
therapy. Minor DDIs usually result in mild effects 
and may not necessitate therapeutic changes. 
 
After data was checked for completeness, it was 
edited, cleaned and analysed. The collected data was 
entered into Epi Info 7 software version 7.1.4 
(Centers for Disease Control and prevention, Atlanta, 
GA) and analysed using IBM SPSS statistics for 
Windows version 21.0.0.0 (IBM Corp. Released 
2012, Armonk, NY: IBM Corp).  Cross tabulation 
was used in bivariate analysis. A test of association 
was done using binary and multiple logistic 
regressions. P value < 0.05 was considered 
significant. Descriptive statistics was used to 
characterize drug-drug interaction. Results of the 
study were organized in the form of frequencies and 
percentages.  
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Ethical clearance: Letter of ethical clearance was 
obtained from the ethical review committee of Addis 
Ababa University, school of pharmacy. Verbal 
consent from a patient was requested to extract data 
from medication charts. Privacy and confidentiality 
was ensured throughout the study. Thus, name and 
address of the patient was not recorded in the data 




Characteristics of study population: A total of 163 
patients were included in the study, of which 83 
(51.9%) were females. The mean age was 37.7 years 
with the maximum number of patients (36.2%) being 
in the age group of 20-34 years. Majority of patients 
(54%) were found to have one to two co-morbidities. 
About one third of patients stay in the hospital a 
week or more. A total of 1202 medications were 
prescribed. Average number of drugs prescribed for a 
patient was 7.4 (SD=3.8). Majority of the study 
subjects (120 cases, 73.6%) received more than 5 
drugs. The average number of diseases per patient 
was 3.1. The disease distribution of the study subjects 
showed a higher incidence of infections (73.6%) 
followed by cardiovascular diseases (47.2%), 
hematologic disorder (26.4%), electrolyte 
abnormalities (21.5%), gastrointestinal disorders 
(15.3%) and others (52.8%). The details of 
demographic and clinical characteristics of the study 
subjects are shown in Table 1. 
 
Potential drug-drug interactions: From 163 patients 
included in the study 141 had at least one pDDI. A 
total of 885 pDDIs, which were comprised of 258 
types of interacting combinations, were identified. 
The overall prevalence of potential drug-drug 
interaction was 86.5%. The number of pDDIs per 
patient vary from 1 to 29. On average 5.4 pDDIs 
occur per a single patient. Large proportion of 
patients (54 [33.1%]) were found to have more than 6 
interacting combination. Patients without any DDI 
were only 22 (13.5%). Larger proportion of pDDIs 
identified was of moderate severity (51.3%) while 
just 19.9% were of major severity. As compared to 
pharmacokinetic type of interaction the 
pharmacodynamic type was found to be more 
common (53.8%). The frequency of interaction 
interms of severity and mechanism is mentioned in 
table 2. 
 
Drugs involved in interaction 
When specific drugs involved in any type of 
interaction were analysed cimetidine (85) was found 
at the top followed by heparin (55), warfarin (51), 
spironolacton (42), tramadol (37), digoxin (36) and 
furosemide (36). Drug pairs frequently involved in 
major DDI were cimetidine/tramadol (22 [12.5%]), 
warfarin/heparin (15 [8.5%]), ceftriaxon/heparin (13 
[7.4%]), cimetidine/prednisolone (9 [5.1%]), 
isoniazide/rifampin (8 [4.5%]) and 
sulfamethoxazole/heparin (7 [4%]). The commonly 
encountered interactions of significant severity were 
spironolacton/furosemide (11), furosemide/digoxin 
(10), spironolacton/digoxin (7) and 
sulfametoxazole/fluconazole (7). The top 10 
interacting pairs of major or moderate severity along 
with their potential adverse outcome are listed in 
table 3.  
 
Risk factors: Age, sex, duration of hospital stay, 
disease type, number of drugs and number of co 
morbidity were studied to determine whether they 
have association with the likelihood of occurrence of 
pDDIs or not. Among these factors only number of 
drugs taken by the patient was found to be 
significantly associated with pDDIs. Multiple logistic 
regression showed that patients who took 5 or more 
drugs are 15.75 times more likely to have at least one 





The present study revealed that the overall incidence 
of potential DDIs were 86.5% which is high as 
compared to other studies which encountered pDDIs 
of 21.3 % - 56.2%.[21-28] This very high incidence of 
pDDI may be because the study was conducted in a 
hospital serving referred patients who have severe 
illnesses and more co morbidities and receive 
multiple drugs which is evidenced by the presence of 
more than 90 % study subjects with at least 1 co-
morbidity, a hospital stay of more than a week for 
about two-third of the patient and average number of 
drug per patient of more than 7. 
 
The number of pDDIs per patient was also high (5.4) 
as compared to studies conducted in Ethiopia as well 
as outside Ethiopia.[27,29] Majority of patients (54 
[33.1%]) were found to have more than 6 interacting 
combination. In contrast to this the study in Pakistan 
found that only10 % of study subjects experience 
more than 6 pDDIs.[27] The result of this study 
indicated that majority of the pDDIs were of 
moderate severity. This is in line with the results of 
many other studies.[21,24,27,30] About one-fifth of 
pDDIs in this study were of major severity. This is a 
similar finding with the result of other studies which 
report 18.3%, 21.2% and 16% of pDDIs to be of 
major severity. [23,27,30] 
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Some of the specific drugs commonly involved in 
pDDI were cimetidine, heparin, warfarin, 
spironolacton, tramadol, digoxin and furosemide. 
Other studies also mention some of these drugs as 
commonly involved drugs in pDDI. For example 
study done in Western Nepal mentions digoxin, 
furosemide and warfarin were drugs frequently 
involved in interaction.[21] The study done by 
Akshaya S. et al and Camelia B. et al  mentioned in 
their list of commonly involved drugs in interaction 
furosemide and spironolacton respectively.[29, 31] 
Cimetidine was frequently involved in interaction 
with various drugs like tramadol, prednisolone, 
dexamethason, warfarin, fluconazole, cotrimoxazole, 
pethidine, hydrocortisone, diazepam, codeine, 
nimodipine, simvastatin and digoxin. The mechanism 
of interaction of cimetidine with these drugs was 
either by inhibiting CYP 450 enzyme or by 
increasing gastric PH. Heparin and warfarin were 
also interact with many other drugs like 
sulfametoxazole, cimetidine, ceftriaxon, fluconazole, 
azithromycin, acetyl salsylic acid which necessitates 
strict blood cogulation monitoring, dose adjustment 
or drug discontinuation based on the outcome of 
interaction. 
 
Drug-pairs that could give rise to potentially severe 
interactions were identified. The judgment here is 
based on theoretical consideration. In clinical 
practice, some of these combinations may still be 
used, but the patient should be closely monitored for 
manifestations such as lack of therapeutic efficacy or 
toxicity, especially for drugs whose therapeutic 
effects may be diminished or augmented when used 
in those combinations.  
 
In the attempt to identify risk factors, the result of 
this study supported published findings that the 
number of drugs taken by a patient is an important 
risk factor for pDDI. Number of drugs used was 
found to be a risk factor for increasing DDIs by a 
number of studies.[21,24,27,29,32]  However sex, age, 
length of hospital stay, type of diagnosis and number 
of comorbidity were not found to affect pDDIs. 
Similar studies also found sex and age are not 
significant factors.[21,29,33] Eventhough some studies 
report in contrast to the present study that length of 
hospital stay [21,27,32] and number of comorbidity 
[21,24,32] are significant factors for pDDI there are some 
studies [29, 33] which also report a similar finding with 
the present study. 
 
Drug interaction is a major factor that might cause 
therapeutic failure or adverse drug reaction to 
patients.[34] As drug interactions can negatively affect 
patient’s clinical outcome, quality of life, as well as 
contribute to unnecessary health care cost, the high 
prevalence rate (86.5%) in this study would make this 
an important area requiring future pharmacists to 
focus on. Identification and prevention of potentially 
harmful DDIs is a critical component in the task of 
clinical pharmacists. So they must remain active in 
their monitoring of pDDIs and make appropriate 
interventions based on the type and severity of 
identified DDIs. Careful selection of drugs, 
appropriate dose adjustments and close patient 
monitoring through active pharmaceutical care 
service is encouraged in order to avoid the negative 
consequences of drug-drug interactions. 
 
The findings of this study may not be generalized 
because it is a single centred study conducted at one 
tertiary care teaching hospital where patients with 
multiple co- morbidity and more advanced disease 
states are seen. It did not also include patients from 
other wards of the hospital where the incidence and 




The present study has showed a high prevalence of 
pDDIs in internal medicine wards. Patients with 
increased number of prescribed medications were at 
higher risk. The study highlighted the need to 
carefully select drugs and implement active 
pharmaceutical care services in order to prevent 
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Table 1: Demographic details and clinical characteristics of the study subjects 
 
Demographic and clinical 
characteristics of patients 
Category Number (%) Mean ± SD 
 (Range) 
Sex Male 80 (49.1)  
Female 83 (50.9) 
Age group (years) <20 20 (12.3) 37.7 ± 17.6 
(14-85) 20-34 59 (36.2) 
35-49 45 (27.6) 
50-64 19 (11.7) 
>65 20 (12.3) 
Hospital stay (days) < 7 57 (35) 11.1 ± 7.4 
(2-36) ≥ 7 106(65) 
Number of co-morbidities 0 16 (9.8) 2.1 ± 1.3 
(0-8) 1-2 88 (54) 
3-4 53 (32.5) 
≥ 5 6 (3.7) 
number of drugs prescribed < 5 43 (26.4) 7.4 ± 3.8 
(2-21) ≥ 5 120 (73.6) 
Diagnosis  GI disorders 25 (15.3%)  
Cardiovascular disease 77 (47.2%) 
Hematologic disorders 43 (26.4%) 
Electrolyte abnormality 35 (21.5%) 
Infectious disease 120(73.6%) 
others 46 (52.8%) 
SD: Standard deviation      
                                                                          GI: Gastrointestinal           
 
 
Table 2: Types of drug-drug interaction identified 
 
Drug-drug interaction 
(DDI) classification method 
Category No of patients with at 
least one interacting 
combination (%) 
N=163  
Number of DDIs 
(%) 
N= 885 
    Mechanism of interaction pharmacokinetics 94 (57.7) 385 (43.5) 
pharmacodynamics 135 (82.8) 476 (53.8) 
unknown 6 (3.7) 24 (2.7) 
Level of severity serious 90 (55.2) 176 (19.9) 
significant 110 (67.5) 454 (51.3) 
minor 102 (62.6) 255 (28.8) 
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Table 3: Top 10 interacting pairs of major or moderate severity along with their potential adverse outcome 
 
 
Table 4: Associated factors for the presence of potential drug-drug interaction 
* Statistically significant. 
COR: crude odds ratio; AOR: adjusted odds ratio; CI: confidence interval. 
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Interacting  pairs frequency severity Potential adverse outcome 
Cimetidine/tramadol 22 major Increase the risk of tramadol side effects 
Warfarin/heparin 15 major Increase bleeding risk  
Ceftriaxon/heparin 13 major Increase bleeding risk 
spironolacton/furosemide 11 Moderate  May cause hypo/hyperkalemia 
furosemide/digoxin 10 Moderate  Increase the risk of digoxin toxicity 
Cimetidine/prednisolone 9 major May increase prednisolone side effect 
Isoniazide/rifampin 8 major Increase risk of hepatotoxicity 
sulfamethoxazole/heparin 7 major Increase bleeding risk 
spironolacton/digoxin  7 Moderate  Increase the risk of digoxin toxicity 
Increase risk of hyperkalemia 
    
sulfametoxazole/fluconazole  7 Moderate  Increase QTc interval 







Sex Male 12(15) 68(85) 1.00 1.00 
Female 10 (12) 73(88) 1.28 (0.52-3.18) 1.16 (0.37-3.63) 
Age <20 3 (15) 17(85) 1.00 1.00 
20-34 8(13.6) 51(86.4) 1.13 (0.27-4.73) 0.58 (0.10-3.41) 
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Number of 
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Number of drugs < 5 17 (39.5) 26 (60.5) 1.00 1.00 
≥5 5 (4.2) 115(95.8) 9.55(3.20-28.48)* 15.75(3.90-63.59)* 
Disease state GI disorders 6 (24) 19 (76) 0.67 (0.24-2.37) 0.45 (0.15-1.36) 
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Infectious disease 13 (10.8) 107 (89.2) 1.93 (0.69-6.81) 2.24 (0.79-6.35) 
others 10 (21.7) 36 (78.3) 1.00 1.00 
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